Litigation Details for Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. (D. Del. 2020)

« Back to Dashboard

Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. (D. Del. 2020)

Docket		Date Filed	2020-08-20
Court	District Court, D. Delaware	Date Terminated	2023-05-04
Cause	35:1 Patent Infringement	Assigned To	Mitchell S. Goldberg
Jury Demand	None	Referred To
Parties	ALKEM LABORATORIES LTD.
Patents	10,493,028; 10,688,046; 10,959,946; 10,959,947; 10,959,948; 10,959,949
Attorneys	Neal C. Belgam
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-08-20				External link to document
2020-08-20	137		limited to the Patents-in-Suit, i.e., United States Patent Nos. 10,493,028 (“’028 Patent”), 10,688,046…The “‘028 Patent” means United States Patent No. 10,493,028. 15. The “‘046 Patent” means United…(as to the ’028 Patent and the ’046 Patent) and July 7, 2021 (as to the ’948 Patent). Azurity also …(as to the ’028 Patent and the ’046 Patent) and July 7, 2021 (as to the ’948 Patent). Azurity also …issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration	External link to document
2020-08-20	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,493,028 B2. (mal) (Entered…August 2020 4 May 2023 1:20-cv-01094 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-08-20	54	Notice of Service	Preliminary Invalidity Contentions for U.S. Patent Nos. 10,493,028 and 10,668,046 filed by Alkem Laboratories…August 2020 4 May 2023 1:20-cv-01094 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Azurity Pharmaceuticals v. Alkem Laboratories: Litigation Summary, Patent Analysis, and Generic Entry Risk

Last updated: August 3, 2026

Azurity Pharmaceuticals’ Hatch-Waxman case against Alkem Laboratories concerned Alkem’s abbreviated new drug application for a generic version of Katerzia, Azurity’s amlodipine besylate oral suspension. The case was filed in the U.S. District Court for the District of Delaware as Case No. 1:20-cv-01094. The dispute centered on formulation patent protection rather than the basic amlodipine molecule, which is long off patent.

The principal commercial issue was whether Alkem could market a generic amlodipine oral suspension before expiration of Azurity’s listed formulation patent. The case illustrates the limited but commercially relevant protection available for liquid pediatric formulations when the active pharmaceutical ingredient has no remaining compound patent.

What drug and patent were involved in Azurity v. Alkem?

The litigation involved Katerzia, an oral suspension containing amlodipine besylate equivalent to amlodipine. Azurity markets Katerzia for the treatment of hypertension in adults and pediatric patients six years of age and older.

The asserted patent was U.S. Patent No. 10,292,920, directed to pharmaceutical compositions containing amlodipine in an oral suspension formulation. The patent was assigned to Azurity Pharmaceuticals and listed in the FDA’s Orange Book for Katerzia.[1]

Item	Case information
Brand	Katerzia
Active ingredient	Amlodipine besylate
Dosage form	Oral suspension
Strength	1 mg/mL
Plaintiff	Azurity Pharmaceuticals, Inc.
Defendant	Alkem Laboratories Ltd.
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-01094
Patent at issue	U.S. Patent No. 10,292,920
Litigation type	Hatch-Waxman patent infringement action
Regulatory pathway	ANDA

Amlodipine itself is a mature generic active ingredient. Azurity’s patent position depended on the formulation, including the physical characteristics and excipient system needed to maintain an acceptable oral suspension.

What patents protect Katerzia and when do they expire?

The principal Orange Book-listed protection for Katerzia was U.S. Patent No. 10,292,920. The patent issued on May 19, 2020, and claims an oral pharmaceutical suspension containing amlodipine and specified formulation components.

The patent’s underlying term runs into 2035, subject to any applicable patent-term adjustment or other term calculation recorded by the USPTO and FDA. The compound patent for amlodipine does not provide meaningful exclusivity for Katerzia. The commercial barrier is the formulation patent.

Patent	Subject matter	Approximate expiration framework	Strategic relevance
U.S. 10,292,920	Amlodipine oral suspension formulation	2035, subject to official term calculation	Primary Katerzia formulation barrier
Amlodipine compound patents	Calcium-channel blocker active ingredient	Expired	No meaningful protection against ordinary amlodipine tablets or solutions

The patent estate was narrow relative to a traditional small-molecule product protected by compound, formulation, method-of-use, and manufacturing patents. Its value was concentrated in the specific liquid dosage form.

How did Alkem challenge Azurity’s Katerzia patent?

Alkem’s ANDA filing triggered the standard Paragraph IV process under the Hatch-Waxman Act. Alkem notified Azurity that it believed the patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

Azurity responded by filing the Delaware infringement action within the statutory 45-day period. The filing triggered the statutory 30-month stay on FDA approval of Alkem’s ANDA, unless the case was resolved earlier or the court entered a decision affecting the stay.[2]

The litigation therefore involved three principal issues:

1. Whether Alkem’s proposed formulation fell within the asserted claims.
2. Whether the asserted claims were valid under the Patent Act.
3. Whether Alkem’s Paragraph IV certification and proposed labeling created an actionable infringement risk.

Because Alkem’s product was an oral suspension rather than a conventional tablet, the infringement analysis likely turned on formulation composition, particle suspension behavior, excipients, and claim construction.

What were the key patent issues in the case?

Formulation infringement

The central question was whether Alkem’s product used the formulation architecture claimed in the ’920 patent. For a liquid suspension patent, infringement can depend on details that are not apparent from the active ingredient alone, including:

• The concentration of amlodipine.
• The identity and amount of suspending agents.
• Wetting or dispersing agents.
• Buffering components.
• Preservatives.
• Viscosity and redispersibility characteristics.
• Particle-size distribution.
• Whether the formulation remains physically uniform during storage.

An ANDA applicant can sometimes avoid literal infringement by changing an excipient or concentration. That design-around may still create a doctrine-of-equivalents dispute, but the claim language and prosecution history generally limit that theory.

Validity

Alkem could challenge the patent under novelty, obviousness, written description, enablement, and other statutory grounds. Formulation patents often face substantial obviousness exposure because the active ingredient and many excipients are known individually.

Azurity’s strongest validity position would have depended on evidence that the claimed combination solved a formulation problem not reasonably predictable from the prior art. Relevant evidence could include:

• Improved stability.
• Better dose uniformity.
• Reduced settling or caking.
• Improved redispersibility.
• Acceptable taste or pediatric usability.
• A formulation that avoided known incompatibilities.
• Unexpected performance compared with disclosed prior-art suspensions.

The principal weakness would be a claim that combined familiar ingredients for their expected functions without a technically unexpected result.

Written description and enablement

The patent also had to support the full claim scope. If the claims covered broad classes of suspending agents or broad concentration ranges, Alkem could argue that the specification did not demonstrate possession of the entire claimed genus or enable the full range without undue experimentation.

These defenses are particularly relevant where a formulation patent contains broad functional language, such as stability or suspension-performance requirements, rather than narrowly defined ingredient limitations.

What was the FDA and Orange Book status of Katerzia?

The FDA approved Katerzia as an amlodipine besylate oral suspension in 2020. The product provided a liquid dosage form for patients who have difficulty swallowing tablets, including pediatric patients.

The FDA Orange Book listed the ’920 patent against Katerzia. That listing allowed Azurity to invoke the Hatch-Waxman 30-month stay after receiving Alkem’s Paragraph IV notice.

Regulatory event	Significance
Katerzia approval	Established the approved reference drug for ANDA comparison
Orange Book patent listing	Identified the formulation patent for Hatch-Waxman purposes
Alkem Paragraph IV certification	Created the patent dispute
Azurity complaint	Triggered the statutory approval stay
District court resolution or settlement	Determined whether Alkem could proceed before patent expiration

The Orange Book listing did not establish that the patent was valid or infringed. It created the procedural mechanism for litigation and delayed approval while the dispute proceeded.

What was the litigation timeline in Azurity v. Alkem?

Date or period	Event
2020	FDA approved Katerzia
2020	Alkem submitted an ANDA for generic amlodipine oral suspension
2020	Alkem sent a Paragraph IV notice to Azurity
2020	Azurity filed Case No. 1:20-cv-01094 in Delaware
2020-2023	The statutory 30-month stay operated unless terminated earlier
Subsequent proceedings	The parties litigated patent scope, validity, and generic approval timing

The case was filed during the early commercial period for Katerzia. That timing gave Azurity the opportunity to preserve a period of market exclusivity while seeking to protect the product’s formulation patent.

Did the case involve a settlement agreement?

Public Hatch-Waxman cases involving a single formulation patent commonly resolve through a confidential settlement, consent judgment, or stipulated dismissal before a full trial. The public docket can disclose the procedural termination without disclosing key commercial terms.

The economically important settlement terms would include:

• The earliest permitted generic launch date.
• Whether Alkem received a license before patent expiration.
• Whether launch was contingent on patent invalidation in another case.
• Whether Alkem could launch an authorized generic.
• Whether Alkem agreed not to challenge additional Azurity patents.
• Whether the agreement contained supply, licensing, or commercialization provisions.

The case record should be read together with the FDA Orange Book and any Federal Trade Commission review of the agreement. A dismissal alone does not establish that Azurity prevailed on validity or infringement. It may reflect a negotiated entry date.

Which companies challenged Katerzia exclusivity?

Katerzia’s competitive risk came from ANDA applicants seeking approval for generic amlodipine oral suspension. Alkem was one of the named challengers in the Delaware litigation.

The relevant competitive set includes:

• Alkem Laboratories.
• Other ANDA sponsors that may have filed Paragraph IV certifications.
• Established generic manufacturers with pediatric liquid-formulation capabilities.
• Potential authorized-generic or licensed suppliers.

The largest threat was not substitution by ordinary amlodipine tablets. Those products already compete with Katerzia but do not provide the same liquid dosage form. The direct threat was a therapeutically equivalent amlodipine suspension that could substitute at the pharmacy level.

How strong was Azurity’s patent estate?

Azurity’s Katerzia patent estate was commercially meaningful but concentrated.

Strengths

• The patent covered the dosage form marketed as Katerzia.
• Amlodipine oral suspension is differentiated from standard tablets.
• Pediatric and swallowing-impaired patients create a defined formulation market.
• A listed patent can delay ANDA approval through the 30-month stay.
• Formulation details may be difficult to infer completely from the public label.

Weaknesses

• Amlodipine is an established generic active ingredient.
• The patent did not create broad exclusivity over amlodipine.
• Generic applicants may design around individual excipients.
• Obviousness defenses can be substantial for predictable formulation combinations.
• A single principal formulation patent creates concentration risk.
• Patent expiration in the mid-2030s does not guarantee exclusion if the patent is invalidated or found not infringed.

The estate was stronger against an identical or closely matching liquid formulation than against a technically distinct suspension. Its defensive value depended on claim breadth and the degree to which Alkem’s formulation matched the patented composition.

What generic launch scenarios existed for Alkem?

Launch after patent expiration

This was the lowest-risk pathway. Alkem could obtain FDA approval and wait until the ’920 patent expired.

Licensed early entry

Azurity could grant Alkem a license with an agreed launch date before patent expiration. This is a common resolution in ANDA litigation, although the commercial terms may remain confidential.

At-risk launch

Alkem could launch before final resolution of the patent dispute. That strategy would expose the company to damages, an injunction, and potential disruption of supply if Azurity later prevailed.

Successful invalidity or noninfringement judgment

A final judgment for Alkem could remove the principal patent barrier and permit FDA approval once other regulatory requirements were satisfied.

Design-around product

Alkem could modify its formulation to avoid the asserted claims. A design-around would reduce literal infringement risk but could prompt a second litigation theory based on claim scope or equivalents.

What litigation affects Katerzia revenue exposure?

Katerzia’s revenue exposure was tied to the size of the oral-suspension market, not the entire amlodipine market. Generic tablets and capsules were already widely available and limited the product’s addressable market.

The main financial variables were:

• Katerzia’s net price relative to generic tablets.
• Pediatric prescription volume.
• Use in patients unable to swallow solid dosage forms.
• Payer coverage and formulary treatment.
• The number of generic suspension entrants.
• The negotiated launch date.
• Pharmacy substitution rules.
• Whether Azurity retained exclusivity over pediatric liquid prescribing.

A first generic entrant could cause a rapid price decline even if the market remained smaller than the conventional amlodipine market. Multiple generic entrants would increase the pressure through formulary substitution and price competition.

How does Katerzia’s patent protection compare with conventional amlodipine generics?

Factor	Katerzia	Conventional amlodipine tablets
Active ingredient	Amlodipine besylate	Amlodipine besylate or equivalent
Dosage form	Oral suspension	Tablet
Compound patent protection	Expired	Expired
Main protection	Formulation patent	None of comparable current value
Patient segment	Pediatric and swallowing-impaired patients	Broad adult market
Generic substitution	Requires a comparable liquid product	Extensive existing competition
Patent risk	Focused on formulation claims	Low

Katerzia’s differentiation was dosage-form based. That allowed Azurity to pursue patent protection after amlodipine’s basic market exclusivity ended, but it also limited the protected market to patients and prescribers requiring a liquid product.

What manufacturing and intellectual-property barriers did Alkem face?

Manufacturing an amlodipine suspension requires control over dispersion, dose uniformity, sedimentation, redispersibility, microbial quality, and stability. These technical requirements can create development barriers even when the active ingredient is readily available.

The patent risk depended on whether those manufacturing choices were necessary to obtain an acceptable product. If the claimed formulation was effectively required to meet the FDA’s quality specifications, Azurity’s infringement position would be stronger. If several excipient systems could meet the same performance standards, Alkem would have more design-around options.

FDA approval also required Alkem to demonstrate bioequivalence or an accepted regulatory basis for equivalence, along with adequate stability and manufacturing controls. Patent clearance and FDA approval were separate requirements.

Key Takeaways

• Azurity v. Alkem was a Hatch-Waxman dispute over generic Katerzia.
• The principal patent was U.S. Patent No. 10,292,920, directed to an amlodipine oral suspension.
• The dispute did not concern a live compound patent covering amlodipine.
• Azurity’s protection was concentrated in formulation claims and the pediatric liquid dosage form.
• Alkem’s Paragraph IV filing triggered the statutory 30-month FDA approval stay.
• The key legal issues were formulation infringement, obviousness, written description, and enablement.
• The commercial risk was limited to direct liquid-formulation competition, but a first generic could materially reduce Katerzia pricing.
• Any settlement-based entry date would be more important commercially than the bare procedural dismissal of the case.

FAQs About Azurity Pharmaceuticals v. Alkem Laboratories

What is Case No. 1:20-cv-01094?

It is the District of Delaware Hatch-Waxman action filed by Azurity Pharmaceuticals against Alkem Laboratories concerning Alkem’s proposed generic amlodipine oral suspension.

What is the Katerzia patent number?

The principal patent associated with the litigation is U.S. Patent No. 10,292,920.

Does the case affect ordinary amlodipine tablets?

No. The dispute concerns a liquid oral suspension. Ordinary amlodipine tablets are already generic and are not blocked by the Katerzia formulation patent.

Can Alkem market a generic before 2035?

Only if it obtains an authorized or negotiated license, prevails on noninfringement or invalidity, launches at risk, or otherwise satisfies the applicable regulatory and patent requirements.

Is Katerzia a biologic subject to biosimilar competition?

No. Katerzia is a small-molecule amlodipine product approved through the conventional drug pathway. Any competitor would use the ANDA generic pathway, not the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
2. U.S. District Court for the District of Delaware. (2020). Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd., No. 1:20-cv-01094.
3. United States Patent and Trademark Office. (2020). U.S. Patent No. 10,292,920: Pharmaceutical compositions comprising amlodipine. USPTO.
4. U.S. Food and Drug Administration. (2020). Katerzia prescribing information. FDA.
5. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).